<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Approach to refractory peptic ulcer disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Approach to refractory peptic ulcer disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Approach to refractory peptic ulcer disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nimish B Vakil, MD, AGAF, FACP, FACG, FASGE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A peptic ulcer is an excavated defect in the gastric or duodenal mucosa that extends through the muscularis mucosa into the deeper layers of the wall. Most peptic ulcers respond to treatment with antimicrobial therapy for
         <em>
          Helicobacter pylori
         </em>
         , withdrawal of nonsteroidal antiinflammatory drugs, or treatment with antisecretory drugs. However, in some individuals, the ulcer is either refractory to conventional therapy or recurs following successful initial treatment.
        </p>
        <p>
         This topic will review the factors associated with refractory ulcer disease, and their diagnosis and management. The clinical manifestations, diagnosis, and initial management of peptic ulcer disease are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/26.html" rel="external">
          "Peptic ulcer disease: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H157828762">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1857995971">
         <span class="h2">
          Refractory peptic ulcer
         </span>
         <span class="headingEndMark">
          —
         </span>
         A refractory peptic ulcer is defined as an endoscopically proven ulcer greater than 5 mm in diameter that does not heal after 8 to 12 weeks of treatment with a proton pump inhibitor.
        </p>
        <p class="headingAnchor" id="H157828825">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the absence of continued nonsteroidal antiinflammatory drug use, acid suppression heals &gt;90 percent of peptic ulcers. However, approximately 5 to 10 percent of ulcers are refractory to 12 weeks of antisecretory therapy with a proton pump inhibitor (PPI). Even with continued PPI use, approximately 5 to 30 percent of peptic ulcers recur within the first year based on whether
         <em>
          Helicobacter pylori
         </em>
         has been successfully eradicated [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3953036315">
         <span class="h1">
          ETIOLOGY AND RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is significant overlap in the risk factors for refractory and recurrent peptic ulceration  (
         <a class="graphic graphic_table graphicRef76314" href="/z/d/graphic/76314.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef101181" href="/z/d/graphic/101181.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3-6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Persistent H. pylori infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Persistent
         <em>
          Helicobacter pylori
         </em>
         can underlie refractory peptic ulceration because this infection was not initially considered, testing was falsely negative, or eradication therapy failed [
         <a href="#rid7">
          7
         </a>
         ]. Failure of eradication therapy may be due to the selection of an inappropriate regimen, antibiotic resistance (particularly to
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ), or poor patient compliance. (See
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults", section on 'Treatment failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1750766076">
         <span class="h2">
          Use of culprit medications
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Continued nonsteroidal anti-inflammatory drug (NSAID) use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Continuing NSAID use is a leading cause of refractory peptic ulceration [
         <a href="#rid7">
          7-9
         </a>
         ]. In an illustrative study that included 60 patients with refractory peptic ulcer and 54 non-refractory matched controls, NSAID and analgesic use was a significant predictor of ulcer refractoriness, present in 40 percent of those with nonhealing ulcers [
         <a href="#rid10">
          10
         </a>
         ]. Forty-four percent of NSAID use was surreptitious and was detected by measuring platelet cyclooxygenase activity.
        </p>
        <p class="headingAnchor" id="H1513031691">
         <span class="h3">
          Other medications/substance use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several medications can cause or exacerbate peptic ulcer disease when used alone or in combination with NSAIDs (eg, glucocorticoids, cytotoxic agents,
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         ,
         <a class="drug drug_general" data-topicid="10061" href="/z/d/drug information/10061.html" rel="external">
          olmesartan
         </a>
         ) [
         <a href="#rid11">
          11,12
         </a>
         ]. Substances (eg, cocaine) can cause peptic ulceration from ischemia due mucosal vasoconstriction [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Non-NSAID medications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Non-occlusive ischemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2021119891">
         <span class="h2">
          Impaired healing
         </span>
        </p>
        <p class="headingAnchor" id="H1421134055">
         <span class="h3">
          Ulcer characteristics
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a subset of patients, refractory ulcers may be caused by an intense inflammatory response, dense scarring, or low mucosal blood flow, which impair angiogenesis and tissue repair [
         <a href="#rid15">
          15
         </a>
         ]. Ulcer size also impacts the healing time. Some studies suggest that large and small gastric ulcers heal at the same rate of approximately 3 mm per week, and thus larger ulcers will require more time to heal [
         <a href="#rid13">
          13
         </a>
         ]. However, another explanation for slow healing in patients with large ulcers is that they are often associated with fibrosis, which in turn adversely affects ulcer healing [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2855061614">
         <span class="h3">
          Comorbid diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Risk factors associated with impaired wound healing include uremia, respiratory failure, organ transplantation, cirrhosis, and a critical illness [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H273671895">
         <span class="h3">
          Smoking
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cigarette smoke and its active ingredients can suppress mucosal cell proliferation and induce apoptosis during ulceration and adversely affect the healing processes [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3874323861">
         <span class="h2">
          Ineffective antisecretory therapy
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Limited adherence or rapid metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited adherence with antisecretory therapy and tolerance to histamine 2 receptor antagonists can contribute to refractory peptic ulceration. Although tolerance does not develop with proton pump inhibitors (PPIs), rapid P450 mediated metabolism might account for incomplete inhibition of acid secretion and failure of PPI therapy in a small subset of patients. Other mechanisms of PPI resistance are rare and still poorly defined. (See
         <a class="medical medical_review" href="/z/d/html/5.html" rel="external">
          "Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H157828607">
         <span class="h3">
          Acid hypersecretory states
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acid hypersecretion is associated with refractory peptic ulceration in patients with Zollinger Ellison syndrome (gastrinoma) [
         <a href="#rid18">
          18
         </a>
         ]. Increased acid production and ulcer disease have been described in patients with primary hyperparathyroidism [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">
          "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Acid hypersecretory states'
         </a>
         .)
        </p>
        <p>
         A small number of patients with acid hypersecretion have neither of these risk factors. Smoking and genetic factors may play an important role in the pathogenesis of these ulcers. A proportion of these patients have idiopathic acid hypersecretion. Idiopathic acid hypersecretion has been defined as a condition with a high basal acid output of 10 mEq/hour or more with a normal basal serum gastrin or a negative
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         test [
         <a href="#rid20">
          20,21
         </a>
         ]. However, all refractory ulcers in these individuals subsequently heal with high-dose antisecretory therapy. (See
         <a class="medical medical_review" href="/z/d/html/2627.html" rel="external">
          "Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19608022">
         <span class="h2">
          Other underlying disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other rare causes of gastric and duodenal ulceration include Crohn disease, sarcoid, lymphoma, ischemia, eosinophilic gastroenteritis, tuberculosis, syphilis, cytomegalovirus, IgG4-related sclerosing disease, and mesenteric ischemia. (See
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Other gastrointestinal features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">
          "Eosinophilic gastrointestinal diseases", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">
          "Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Gastric lymphoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1238.html" rel="external">
          "Abdominal tuberculosis", section on 'Intestinal tuberculosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Gastrointestinal manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">
          "Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Gastrointestinal findings'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">
          "Overview of extrapulmonary manifestations of sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2364467681">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory ulcers are suspected in patients with peptic ulcer disease with persistent or recurrent dyspepsia. They are diagnosed at upper endoscopy performed for evaluation of symptoms or on routine endoscopic surveillance after initial therapy for peptic ulcer disease. (See
         <a class="medical medical_review" href="/z/d/html/25.html" rel="external">
          "Peptic ulcer disease: Treatment and secondary prevention", section on 'Repeat upper endoscopy in selected patients'
         </a>
         .)
        </p>
        <p>
         Upper endoscopy in patients with refractory ulcers can also help determine the underlying etiology. Biopsies of gastric ulcers should be performed to exclude an underlying malignancy and other causes of ulceration (eg, Crohn disease, sarcoid, eosinophilic gastroenteritis). If possible, we obtain biopsies from four quadrants of the ulcer. If endoscopic features suspicious for malignancy (eg, nodularity at the edges of the ulcer or infiltration of the surrounding tissue creating a heaped up appearance at the edge of the ulcer), we obtain biopsies using jumbo forceps with more extensive sampling along the edges of the ulcer. In addition, we biopsy the gastric antrum and body for
         <em>
          Helicobacter pylori
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Endoscopic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H528990663">
         <span class="h2">
          Address the etiology and risk factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Re-evaluate risk factors
         </strong>
         – In patients with refractory ulcers, it is important to reevaluate the underlying etiology and risk factors for peptic ulcer disease. Key elements of the history include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Compliance with antisecretory therapy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Continued nonsteroidal anti-inflammatory drug (NSAID) use
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of medications/substances associated with peptic ulcers or that may impact healing
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Risk factors associated with poor ulcer healing (smoking, co-morbid diseases) (see
         <a class="local">
          'Comorbid diseases'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients for whom the etiology remains uncertain based on the history and biopsy results from the upper endoscopy that established their diagnosis, selected laboratory testing (fasting serum gastrin and serum calcium levels) may help elucidate the underlying etiology. (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Evaluation of H. pylori and NSAID negative ulcers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eradicate
         </strong>
         <strong>
          <em>
           Helicobacter pylori
          </em>
         </strong>
         <strong>
          (
         </strong>
         <strong>
          <em>
           H.
          </em>
         </strong>
         <em>
         </em>
         <strong>
          <em>
           pylori
          </em>
         </strong>
         <strong>
          )
         </strong>
         – Most patients with refractory ulceration have
         <em>
          H. pylori.
         </em>
         Eradication of
         <em>
          H. pylori
         </em>
         improves ulcer healing rates in patients with peptic ulcers [
         <a href="#rid7">
          7,22-25
         </a>
         ]. In patients with refractory ulcers who do not have evidence of
         <em>
          H. pylori
         </em>
         on gastric biopsies, we perform immunohistochemistry routinely to confirm the negative result. In patients treated for
         <em>
          H. pylori
         </em>
         , eradication of infection should be confirmed four or more weeks after the completion of therapy. (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Confirm eradication in all patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoid culprit medications and tobacco
         </strong>
         – Patients should be advised to avoid NSAIDs. We also advise cessation of tobacco use given that it affects gastric microcirculation adversely and impairs ulcer healing [
         <a href="#rid26">
          26-30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/22.html" rel="external">
          "Peptic ulcer disease: Epidemiology, etiology, and pathogenesis", section on 'Smoking'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treat the underlying cause
         </strong>
         – Patients with other causes of ulceration (eg, Crohn disease, sarcoidosis) require concurrent treatment to facilitate ulcer healing and prevent recurrence. (See
         <a class="medical medical_review" href="/z/d/html/23.html" rel="external">
          "Unusual causes of peptic ulcer disease", section on 'Etiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H90333298">
         <span class="h2">
          Antisecretory therapy
         </span>
        </p>
        <p>
         Twice-daily dosing (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         20 mg twice daily) is usually effective in inducing healing in patients with ulcers that were refractory to once-daily standard dose proton pump inhibitor (PPI) [
         <a href="#rid3">
          3
         </a>
         ]. After 12 additional weeks of PPI therapy, we perform a repeat upper endoscopy to assess ulcer healing and obtain additional biopsies. Long-term maintenance acid inhibitory therapy (eg, omeprazole 20 mg daily) should be routinely offered to these patients once the ulcer has healed (see
         <a class="local">
          'Repeat upper endoscopy'
         </a>
         below). Some experts recommend changing the PPI when the initial treatment fails and a second course is being considered [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         PPIs are the preferred therapy for refractory ulcer disease. Healing rates for duodenal ulcers, and to a lesser extent gastric ulcers, are associated with the degree of inhibition of acid secretion [
         <a href="#rid31">
          31,32
         </a>
         ]. In a report of patients with refractory ulcers after three months of histamine-2 receptor antagonist (H2RA) therapy, a 40 mg dose of
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         produced better healing than continued standard H2RA (96 versus 57 percent) [
         <a href="#rid33">
          33
         </a>
         ]. With antisecretory therapy with a PPI, &gt;90 percent of refractory ulcers heal with an additional eight weeks of treatment. Potassium competitive acid inhibitors are comparable to PPIs in preventing NSAID-related ulcer disease. Vonoprazan, a potassium competitive acid blocker, has been widely studied in Japan where idiopathic peptic ulcer disease is often refractory to conventional PPI therapy [
         <a href="#rid34">
          34
         </a>
         ]. Vonoprazan may have high healing rates in this population (&gt;80 percent healing), but is not available in many countries [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2294557">
         <span class="h2">
          Repeat upper endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with refractory ulcers, endoscopy should be performed after 12 weeks of additional treatment with a PPI. This endoscopy serves to document ulcer healing.
        </p>
        <p>
         We biopsy the ulcer scar if the ulcer has healed as some neoplastic ulcers can heal with antisecretory therapy. If the ulcer has not healed, we obtain biopsies from four quadrants of the ulcer ideally using jumbo forceps with more extensive sampling along the edges of the ulcer. In addition, we biopsy the gastric antrum and body for
         <em>
          H. pylori
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/18.html" rel="external">
          "Indications and diagnostic tests for Helicobacter pylori infection in adults", section on 'Endoscopic testing'
         </a>
         .)
        </p>
        <p>
         Biopsies for culture and sensitivity should be performed to guide antibiotic therapy in patients with persistent
         <em>
          H. pylori
         </em>
         infection after two courses of antibiotic treatment. (See
         <a class="medical medical_review" href="/z/d/html/7.html" rel="external">
          "Treatment regimens for Helicobacter pylori in adults", section on 'Confirm eradication in all patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3485030624">
         <span class="h2">
          Surgery in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical management is rarely required and is reserved for the peptic ulcers that fail to heal after twice-daily antisecretory therapy with a PPI for 24 weeks in whom other correctable factors (eg, medication noncompliance, NSAID use, and
         <em>
          H. pylori
         </em>
         infection) have been addressed. Malignancy is rare in duodenal ulcer disease, but surgery may be indicated for chronic nonhealing gastric ulcers as they may harbor a malignancy that is sometimes not detected despite extensive endoscopic biopsy. Indications for surgical management of peptic ulcer disease and surgical treatment options are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8040.html" rel="external">
          "Surgical management of peptic ulcer disease", section on 'Indications for peptic ulcer surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H216705358">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117855.html" rel="external">
          "Society guideline links: Peptic ulcer disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H92573724">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15735.html" rel="external">
          "Patient education: Peptic ulcers (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15734.html" rel="external">
          "Patient education: H. pylori infection (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2016.html" rel="external">
          "Patient education: Peptic ulcer disease (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/2012.html" rel="external">
          "Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A refractory peptic ulcer is defined as an endoscopically proven ulcer greater than 5 mm in diameter that does not heal after 12 weeks of treatment with a proton pump inhibitor (PPI). (See
         <a class="local">
          'Terminology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of continued nonsteroidal anti-inflammatory drug (NSAID) use, acid suppression heals &gt;90 percent of peptic ulcers. However, approximately 5 to 10 percent of ulcers are refractory to 12 weeks of antisecretory therapy with a PPI. Even with continued PPI use, approximately 5 to 30 percent of peptic ulcers recur within the first year. While there are several factors that are associated with refractory gastric/duodenal ulceration, persistent
         <em>
          Helicobacter pylori
         </em>
         (
         <em>
          H. pylori
         </em>
         ) infection and NSAID use are the two main causes. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractory ulcers are suspected in patients with peptic ulcer disease with persistent or recurrent dyspepsia. They are diagnosed at upper endoscopy performed for evaluation of symptoms or on routine endoscopic surveillance after initial therapy for peptic ulcer disease. Biopsies of the ulcer to exclude an underlying malignancy and other causes of ulceration (eg, Crohn disease, sarcoid). In addition, we obtain biopsies of the antrum and body to diagnose or ex
         <em>
          clude H. pylori
         </em>
         . In patients with refractory ulcers who do not have eviden
         <em>
          ce of H. pylori
         </em>
         on gastric biopsies, we perform additional testing to confirm the negative result. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with refractory ulcers should be evaluated for continued NSAID use, the use of other medications associated with peptic ulcers, and comorbidities and other factors that may contribute to poor ulcer healing and recurrence. Fasting serum gastrin and total calcium levels should be measured to exclude Zollinger-Ellison syndrome and hyperparathyroidism, respectively. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should be advised to avoid NSAIDs and tobacco. Patients with
         <em>
          H. pylori
         </em>
         should be treated with a goal of eradication of
         <em>
          H. pylori
         </em>
         infection. Eradication of infection should be confirmed after the completion of therapy. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with refractory peptic ulcer disease, the mainstay of therapy is additional antisecretory therapy. For patients who fail to respond to standard doses of PPI (eg,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         40 mg daily), twice-daily dosing is usually effective in inducing healing. We perform a repeat endoscopy to document ulcer healing following 12 additional weeks of PPI therapy. Surgical management is reserved for the gastric ulcers that fail to heal after twice-daily antisecretory therapy with a PPI for 24 weeks in whom other correctable factors (eg, medication noncompliance, NSAID use, and
         <em>
          H. pylori
         </em>
         infection) have been addressed. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2172157052">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Andrew H. Soll, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol 2006; 3:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardhan KD, Nayyar AK, Royston C. History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. Dig Liver Dis 2003; 35:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman AJ, Kerrigan DD, Johnson AG. Effect of the pre-operative response to H2 receptor antagonists on the outcome of highly selective vagotomy for duodenal ulcer. Br J Surg 1987; 74:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HU. Diagnostic and Treatment Approaches for Refractory Peptic Ulcers. Clin Endosc 2015; 48:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanas A, Remacha B, Sáinz R, Hirschowitz BI. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol 2000; 95:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschowitz BI, Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998; 114:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 2002; 34:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanas AI, Remacha B, Esteva F, Sáinz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. Aliment Pharmacol Ther 2015; 42:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moriya K, Kojima K, Kawaratani H, et al. A rare case of refractory and severe duodenal ulcers associated with olmesartan. Gastrointest Endosc 2021; 94:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           STEIGMANN F, SHULMAN B. The time of healing of gastric ulcers: implications as to therapy. Gastroenterology 1952; 20:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds JC, Schoen RE, Maislin G, Zangari GG. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Am J Gastroenterol 1994; 89:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih SC, Tseng KW, Lin SC, et al. Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer. World J Gastroenterol 2005; 11:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng GY, Lin HJ, Fang CT, et al. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. Aliment Pharmacol Ther 2007; 26:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Ren JW, Wong CC, et al. Effects of cigarette smoke and its active components on ulcer formation and healing in the gastrointestinal mucosa. Curr Med Chem 2012; 19:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annibale B, De Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994; 8:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparoni P, Caroli A, Sardeo G, et al. [Primary hyperparathyroidism and peptic ulcer]. Minerva Med 1989; 80:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis JH. Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders. Aliment Pharmacol Ther 1991; 5 Suppl 1:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collen MJ, Stanczak VJ, Ciarleglio CA. Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication). Dig Dis Sci 1989; 34:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd HK, Zaterka S, Eisig JN, et al. Helicobacter pylori and refractory duodenal ulcers: cross-over comparison of continued cimetidine with cimetidine plus antimicrobials. Am J Gastroenterol 1994; 89:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantzaris GJ, Hatzis A, Tamvakologos G, et al. Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates. Dig Dis Sci 1993; 38:1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arkkila PE, Kokkola A, Seppälä K, Sipponen P. Size of the peptic ulcer in Helicobacter pylori-positive patients: association with the clinical and histological characteristics. Scand J Gastroenterol 2007; 42:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avsar E, Kalayci C, Tözün N, et al. Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 1996; 8:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walt RP, Daneshmend TK. Resistant duodenal ulcer: when, why and what to do? Postgrad Med J 1988; 64:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan FK, Sung JJ, Lee YT, et al. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? Am J Gastroenterol 1997; 92:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardhan KD, Graham DY, Hunt RH, O'Morain CA. Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole. Helicobacter 1997; 2:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li LF, Chan RL, Lu L, et al. Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review). Int J Mol Med 2014; 34:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993; 7 Suppl 1:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018; 67:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugawara K, Koizumi S, Horikawa Y, et al. Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan. J Gastroenterol 2019; 54:963.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 27 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8613015" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9732917" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16456574" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Peptic ulcer disease today.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14567455" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2889503" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of the pre-operative response to H2 receptor antagonists on the outcome of highly selective vagotomy for duodenal ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26240800" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diagnostic and Treatment Approaches for Refractory Peptic Ulcers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10685760" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9558275" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11960062" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7557077" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Risk factors associated with refractory peptic ulcers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26096497" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33965381" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A rare case of refractory and severe duodenal ulcers associated with olmesartan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14897083" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The time of healing of gastric ulcers: implications as to therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8147361" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15609413" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Expression patterns of transforming growth factor-beta and its receptors in gastric mucosa of patients with refractory gastric ulcer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17767477" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22300077" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effects of cigarette smoke and its active components on ulcer formation and healing in the gastrointestinal mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8186351" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2622574" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : [Primary hyperparathyroidism and peptic ulcer].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1888834" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2914544" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8079928" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Helicobacter pylori and refractory duodenal ulcers: cross-over comparison of continued cimetidine with cimetidine plus antimicrobials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8508709" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505991" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Size of the peptic ulcer in Helicobacter pylori-positive patients: association with the clinical and histological characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8804873" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2904675" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Resistant duodenal ulcer: when, why and what to do?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15225176" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Seven-day therapy for Helicobacter pylori in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9068465" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9432318" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effects of smoking on cure of Helicobacter pylori infection and duodenal ulcer recurrence in patients treated with clarithromycin and omeprazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859303" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cigarette smoking and gastrointestinal diseases: the causal relationship and underlying molecular mechanisms (review).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2142113" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2151756" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The relationship between suppression of acidity and gastric ulcer healing rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8490075" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Is there any acid peptic disease that is refractory to proton pump inhibitors?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29196436" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31037448" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Is the new potent acid-inhibitory drug vonoprazan effective for healing idiopathic peptic ulcers? A multicenter observational study in Akita Prefecture, Japan.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
